Predicting the HER2 status of breast cancer from basic histopathology data: an analysis of 1500 breast cancers as part of the HER2000 International Study

Bilous, Michael; Ades, C.; Armes, Jane E.; Bishop, Jennifer; Brown, Robert W.; Cooke, Bridget E.; Cummings, Margaret C.; Farshid, Gelareh; Field, Andrew; Morey, Adrienne; McKenzie, Paul; Raymond, Wendy A.; Robbins, Peter; Tan, Lisa

doi:10.1016/s0960-9776(02)00273-4

Cited by 89 publications

(55 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Some studies have found significant interobserver variability between pathologists in grading the intensity of HER2 staining by IHC. 3,10,16,19,27 High concordance of results between FISH and IHC with strong (3ϩ) staining and negative (0 to 1ϩ) staining are generally seen. However, a marked discordance in the classification of results is seen between the two methods in cases with weak (2ϩ) HER2 staining by IHC.…”

Section: Discussionmentioning

confidence: 93%

“…11,14,16,28 Approximately 23 to 26% of cases with weak (2ϩ) HER2 staining by IHC show gene amplification by FISH testing. 1,5,10,29,30 Studies by Bloom and Harrington 3 and Lehr and colleagues 7 found that computer-assisted image analysis significantly increased the correlation of IHC and FISH results.…”

Section: Discussionmentioning

confidence: 99%

“…Overexpression of HER2 is rare in invasive lobular carcinoma (0.8%) and other specialized types of breast carcinomas. 8,10 Studies have shown that the most common mechanism (90 to 96%) of HER2 overexpression is gene amplification. 2,9,11,12 Widely used approaches to assess HER2 status include immunohistochemistry (IHC) to determine protein expression and fluorescent in situ hybridization (FISH) to determine HER2 gene copy number.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Analysis of HER2 Gene Amplification Using an Automated Fluorescence in Situ Hybridization Signal Enumeration System

Stevens

Almanaseer

González

et al. 2007

The Journal of Molecular Diagnostics

View full text Add to dashboard Cite

The HER2 gene, amplified in 10 to 35% of invasive human breast carcinomas, has prognostic and therapeutic implications. Fluorescent in situ hybridization is one method currently used for assessing HER2 status, but fluorescent in situ hybridization involves the time-consuming step of manual signal enumeration. To address this issue , Vysis has developed an automated signal enumeration system , Vysis AutoVysion. A multicenter , blinded study was conducted on 39 formalin-fixed , paraffin-embedded invasive breast carcinoma specimens , including 20 HER2 nonamplified and 19 HER2 amplified (weakly to highly amplified) , provided in duplicate to each study site for analysis. Calculation of the HER2/CEP17 ratio and the hands-on time of both manual and automated enumeration approaches were compared. Overall agreement of HER2 classification results (positive and negative) was 92.5% ( The HER2 gene (ERBB2) is located on chromosome 17 (q11.2-q12) and encodes a 185-kd transmembrane glycoprotein with intracellular tyrosine kinase activity, which is closely related to the epidermal growth factor receptor.1-6 Overexpression of the HER2 oncogene seems to stimulate growth and cellular motility and has been implicated in several malignancies. 4,6,7 Approximately 10 to 35% of invasive human breast carcinomas are associated with HER2 protein overexpression.2,6,8 HER2 overexpression is considered an unfavorable prognostic factor and is associated with better response rates to trastuzumab (Herceptin) therapy and anthracycline-based chemotherapy regimens. 9 Most breast carcinomas that overexpress HER2 are invasive ductal adenocarcinomas (95.5%) and are high-grade tumors [histopathological grades 2 (28%) or 3 (69%)]. Overexpression of HER2 is rare in invasive lobular carcinoma (0.8%) and other specialized types of breast carcinomas. 8,10 Studies have shown that the most common mechanism (90 to 96%) of HER2 overexpression is gene amplification. 2,9,11,12 Widely used approaches to assess HER2 status include immunohistochemistry (IHC) to determine protein expression and fluorescent in situ hybridization (FISH) to determine HER2 gene copy number. 4,11,[13][14][15] Reportedly, FISH has shown greater interlaboratory concordance and has been found to be a better predictor of response to trastuzumab (Herceptin) therapy, as compared with IHC.

show abstract

Section: Discussionmentioning

confidence: 93%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Analysis of HER2 Gene Amplification Using an Automated Fluorescence in Situ Hybridization Signal Enumeration System

Stevens

Almanaseer

González

et al. 2007

The Journal of Molecular Diagnostics

View full text Add to dashboard Cite

show abstract

“…No quantitative protein measurements were done because, currently, no Western blot technique for the combined a v h 3 integrin subunits is available. However, we think that for most future applications of [ 18 F]Galacto-RGD PET in patients, a semiquantitative assessment of a v h 3 expression would be sufficient, similar for example to the semiquantitative analysis of HER-2/ neu expression with immunohistochemistry in breast cancer by the DAKO score before starting Herceptin therapy (32). Moreover, for an exact quantification of receptor density in PET, dynamic scans with arterial blood sampling would probably have to be done over the tumor area in addition to static emission scans, limiting the use of […”

Section: Discussionmentioning

confidence: 99%

Positron Emission Tomography Using [18F]Galacto-RGD Identifies the Level of Integrin αvβ3 Expression in Man

Beer¹,

Haubner

Sarbia³

et al. 2006

Clinical Cancer Research

322

221

View full text Add to dashboard Cite

Purpose: The integrin a v h 3 plays a key role in angiogenesis and tumor cell metastasis and is therefore an important target for new therapeutic and diagnostic strategies. We have developed [18 F]Galacto-RGD, a highly a v h 3 -selective tracer for positron emission tomography (PET). Here, we show, in man, that the intensity of [ 18 F]Galacto-RGD uptake correlates with a v h 3 expression. Experimental Design: Nineteen patients with solid tumors (musculoskeletal system, n = 10; melanoma, n = 4; head and neck cancer, n = 2; gliobastoma, n = 2; and breast cancer, n = 1) were examined with PET using [

show abstract

“…Indeed, Yaziji et al observed 18.6% HER2+ expression in a large volume quality control program [12]. Bilous et al reported 12% HER2+ expression in the HER2000 International Study [13]. Yang et al observed 14% HER2+ in a Poland populationbased case control study [3].…”

Section: Frequency Distribution For Her2 (±) And/or Er (±) Expressionmentioning

confidence: 99%

Human epidermal growth factor receptor-2 and estrogen receptor expression, a demonstration project using the residual tissue respository of the Surveillance, Epidemiology, and End Results (SEER) program

Anderson

Luo

Chatterjee

et al. 2008

Breast Cancer Res Treat

View full text Add to dashboard Cite

Background-In 2001, the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program established Residual Tissue Repositories (RTR) in the Hawaii, Iowa, and Los Angeles Tumor Registries to collect discarded tissue blocks from pathologic laboratories within their catchment areas. To validate the utility of the RTR for supplementing SEER's central database, we assessed human epidermal growth factor receptor-2 (HER2) and estrogen receptor expression (ER) in a demonstration project.

show abstract

Predicting the HER2 status of breast cancer from basic histopathology data: an analysis of 1500 breast cancers as part of the HER2000 International Study

Cited by 89 publications

References 19 publications

Analysis of HER2 Gene Amplification Using an Automated Fluorescence in Situ Hybridization Signal Enumeration System

Analysis of HER2 Gene Amplification Using an Automated Fluorescence in Situ Hybridization Signal Enumeration System

Positron Emission Tomography Using [18F]Galacto-RGD Identifies the Level of Integrin αvβ3 Expression in Man

Human epidermal growth factor receptor-2 and estrogen receptor expression, a demonstration project using the residual tissue respository of the Surveillance, Epidemiology, and End Results (SEER) program

Contact Info

Product

Resources

About